Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. [electronic resource]
Producer: 20051207Description: 505-16 p. digitalISSN:- 1524-9557
- Adult
- Antigens, CD34 -- biosynthesis
- Antigens, Neoplasm -- biosynthesis
- Cancer Vaccines
- Cell Proliferation
- Dendritic Cells -- cytology
- Disease Progression
- Disease-Free Survival
- Enzyme-Linked Immunosorbent Assay
- HLA-A Antigens -- biosynthesis
- HLA-A2 Antigen
- Humans
- Immunotherapy, Adoptive -- methods
- Influenza A virus -- chemistry
- Interferon Type I -- therapeutic use
- Interferon-alpha -- metabolism
- Interferon-gamma -- metabolism
- MART-1 Antigen
- Melanoma -- immunology
- Membrane Glycoproteins -- biosynthesis
- Middle Aged
- Monophenol Monooxygenase -- biosynthesis
- Neoplasm Proteins -- biosynthesis
- Peptide Fragments -- chemistry
- Peptides -- therapeutic use
- Stem Cells -- cytology
- Time Factors
- Treatment Outcome
- Viral Matrix Proteins -- chemistry
- gp100 Melanoma Antigen
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.